By Aurora Berra, Head of Global Patient Affairs Biological endpoints are essential, but on their own, they cannot tell the
Category: Science
A bridge to the field: how real-world data informs rare disease care
“We try to identify and understand how to better support patients outside the context of clinical trials.” As a Field
Rethinking discovery: how powerful screening tools are redefining the search for new medicines
By Mary Jane Hinrichs, SVP Head of Early Development and Innovation In medicine discovery, identifying the right biological target has
When science advances, understanding must keep pace
Aurora Berra, Vice President Global Patient Officer We are living in an era of extraordinary scientific progress. We can target
Why evidence matters: Seema Meloni on making data meaningful
“In order to help all partners understand the value of a medicine, we provide the wrap-around support of data coming
From molecule to medicine: the process behind patient-ready treatments
“We need to make sure that it’s scalable, safe, and reproducible—so that every patient gets the same medicine every time.” As
When bile acids tell a bigger story: how cholestatic biology is reshaping rare liver disease research
. Jennifer Schranz, Senior Vice President, Head of Rare Diseases The human cost of a system out of balance Over
Testing the hypothesis: a focused pilot for AI in healthcare
Every scientific breakthrough begins with a question: can this medicine extend life, restore balance, or meaningfully change what is possible
Always one step ahead: Anne Petit on making medicines happen
Anne Petit does not wait for instructions. She knows that in pharmaceutical development, her team often moves first. “We always
